GLP-1 Alternatives for Weight Loss: Evidence-Based Options if You Can't Access These Drugs
Medically Reviewed by
Board Certified Internal Medicine
Published
Mar 13, 2026
Last Reviewed
Mar 18, 2026
Sources
5 peer-reviewed
Standard
YMYL / E-E-A-T
GLP-1 Alternatives: A Comparison of All FDA-Approved Options
If GLP-1 receptor agonists are not accessible — due to cost, supply shortages, medical contraindications, or insurance denial — there are five FDA-approved pharmacological alternatives for weight management, plus robust evidence for several non-pharmacological approaches. No alternative matches the 15–22% body weight reduction seen with semaglutide or tirzepatide, but the best alternatives can produce 5–10% sustained weight loss, which still provides meaningful metabolic and cardiovascular benefit. Choosing the right alternative depends on your cardiovascular risk profile, psychiatric history, tolerance for side effects, and cost constraints.
Phentermine/Topiramate (Qsymia): Most Effective Non-GLP-1 Option
Phentermine/topiramate extended-release (Qsymia) produces the highest weight loss among non-GLP-1 FDA-approved medications — an average of 8–10% body weight reduction at the highest dose (15mg/92mg) in the CONQUER and EQUIP trials. It works through dual mechanisms: phentermine reduces appetite (sympathomimetic), and topiramate enhances satiety (mechanism not fully understood but involves GABA and glutamate modulation). Cost is approximately $180–220/month. Key limitations include: it is contraindicated in pregnancy (topiramate is teratogenic, FDA Risk Category X), in patients with cardiovascular disease (phentermine raises heart rate and blood pressure), hyperthyroidism, or a history of glaucoma. Cognitive side effects (word-finding difficulties, memory issues) occur in approximately 5–8% of patients.
Naltrexone/Bupropion (Contrave): Best for Emotional or Reward-Driven Eating
Naltrexone/bupropion (Contrave) targets the hypothalamic dopamine/opioid pathways that drive reward-based eating. In the COR-1 trial, patients lost an average of 5–6% body weight vs 1% placebo at 56 weeks. Uniquely among weight loss medications, Contrave addresses the psychological reward component of eating — making it particularly valuable for patients who describe compulsive or emotional eating patterns. It is contraindicated in patients using opioid medications (naltrexone blocks opioid receptors) and in patients with uncontrolled seizure disorder, severe hepatic disease, or those undergoing opioid withdrawal. Cost is approximately $100–180/month with savings cards.
Orlistat (Xenical / Alli): Safest Option with Lowest Efficacy
Orlistat inhibits pancreatic lipase, preventing absorption of approximately 30% of dietary fat. Average weight loss is 3–4% greater than placebo in clinical trials — the lowest of all FDA-approved options. However, orlistat has an excellent safety profile (no systemic absorption), is available OTC at half the prescription dose (Alli, 60mg vs prescription Xenical 120mg), and costs approximately $50–80/month. Its most significant downside is GI: unabsorbed fat causes oily spotting, loose stools, fecal urgency, and incontinence — particularly after high-fat meals. These effects are dose-dependent and can be significantly reduced by following a low-fat diet while taking orlistat. Orlistat can also reduce absorption of fat-soluble vitamins (A, D, E, K) and oral contraceptives — supplementation and timing adjustments are required.
Setmelanotide (Imcivree): For Rare Genetic Obesity Conditions
Setmelanotide (Imcivree) is FDA-approved for a narrow indication: obesity caused by specific genetic deficiencies in the MC4R pathway, including POMC, PCSK1, or LEPR deficiency. It is not a general weight loss medication but can produce 25–30% weight reduction in the genetically-confirmed patient population. If standard weight loss medications have failed despite adherence, and your physician suspects a genetic cause of severe early-onset obesity, genetic testing through a specialized obesity medicine center may identify rare pathway deficiencies where setmelanotide could be indicated.
Intensive Lifestyle Intervention: Evidence-Based Non-Drug Option
The Diabetes Prevention Program (DPP) demonstrated that intensive lifestyle intervention (7% body weight loss through 150+ minutes/week of moderate activity and structured dietary counseling) reduced diabetes progression by 58% — more than metformin. The Look AHEAD trial showed that intensive lifestyle intervention produced and maintained approximately 4–8% weight loss at 10 years with structured support. Behavioral therapy (cognitive-behavioral therapy for weight loss, motivational interviewing) combined with a structured meal plan and exercise program can produce 5–7% weight loss, with results sustained when the program includes long-term follow-up. The key evidence finding is that the most effective lifestyle interventions involve frequent contact (16+ visits in year one), consistent tracking, and group support — not generic advice to eat less and move more.
Emerging Options: Cagrilintide, Retatrutide, and What's Coming
Several medications in late-stage development may provide GLP-1-level efficacy as alternatives or combinations. Retatrutide (Eli Lilly), a triple receptor agonist (GLP-1/GIP/glucagon), showed 24% weight loss at 48 weeks in phase 2 trials — exceeding even tirzepatide. Cagrilintide/semaglutide combination (CagriSema, Novo Nordisk) showed 22% weight loss in phase 2. Oral GLP-1 alternatives with improved bioavailability are in development. These drugs are expected in FDA review 2025–2026, with potential approvals in 2026–2027. They represent the next generation of obesity pharmacotherapy for patients who cannot tolerate or access current GLP-1 options.
Frequently Asked Questions
These answers are for informational purposes only. Always consult your physician for personalized medical advice.
Was this article helpful?
Scientific References & Further Reading
- Wilding JPH et al. — Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021.
- Jastreboff AM et al. — Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022.
- FDA Drug Approvals Database — GLP-1 Receptor Agonists. U.S. Food & Drug Administration.
- PubMed — GLP-1 Receptor Agonist Research Index. National Library of Medicine.
- Mayo Clinic — GLP-1 Agonists for Type 2 Diabetes and Obesity. Mayo Clinic Proceedings.
This content is produced in accordance with GLP-1 Health's editorial standards and is based on peer-reviewed clinical evidence from the sources cited above. It does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.
